Development of a treatment algorithm for kinase inhibitor therapy in CML. [ 2012 - 2014 ]

Also known as: Individualised therapy for CML patients based on drug sensitivity studies

Research Grant

[Cite as]

Researchers: Prof Timothy Hughes (Principal investigator) ,  Prof Deborah White Prof John Rasko

Brief description Chronic myeloid leukaemia has become a highly treatable condition since targeted therapy became available. There are now 3 highly effective drugs available, imatinib, nilotinib and dasatinib. We are developing drug sensitivity assays that can be used to predict response to these 3 drugs. We propose that these assays could be used to individualise therapy to ensure that the optimal drug can be provided for each patient from diagnosis to provide a cost-effective customized approach to therapy.

Funding Amount $AUD 527,761.87

Funding Scheme Project Grants

Notes Standard Project Grant

Viewed: [[ro.stat.viewed]]